Daiichi Sankyo Yuhan and Pfizer's new indication for patritumab deruxtecan has been approved in China.

On August 12, Daiichi Sankyo announced that the new indication for Enhertu has been approved in China. The approved indication is: this product in combination with patritumab is indicated for first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.